Table 2 Clinical features of participants.

From: Evaluation of the p53 pathway in polycystic ovarian syndrome pathogenesis and apoptosis enhancement in human granulosa cells through transcriptome data analysis

Variablea

Control (18)

PCOS (20)

p-valuec

Age (years)

32.72 ± 1.10

31.71 ± 0.65

 > 0.05

AMH (ng/ml)

3.48 ± 1.095

11.07 ± 3

 < 0.05

BMI (kg/m2)

24.13 ± 0.85

26.58 ± 0.56

 > 0.05

FBS (mg/dl)

99.11 ± 3.98

92.23 ± 3.54

 > 0.05

FSH (mUI/ml)

5.25 ± 0.70

5.32 ± 0.6

 > 0.05

LH (mUI/ml)

4.44 ± 0.74

7.57 ± 1.19

 < 0.0001

LH/FSH ratio

0.87 ± 0.056

1.66 ± 0.24

 < 0.05

PRL (ng/ml) b

15.40 (1th 11.06, 3th 27.0)

16.40 (1th 10.63, 3th 28.0)

 > 0.05

T3 (ng/ml)

97.05 ± 2.17

76.06 ± 25.03

 > 0.05

T4 (ng/ml)

10.3 ± 1.53

8.04 ± 0.35

 = 0.05

TSH (IU/L)

2.01 ± 0.27

2.54 ± 0.32

 > 0.05

Vitamin D (ng/ml)

30.86 ± 5.40

32.61 ± 3.22

 > 0.05

  1. AMH Anti Mullerian Hormone, BMI Body Mass Index; FBS Fasting Blood Sugar; FSH Follicle Stimulating Hormone; LH Luteinizing Hormone; PCOS Polycystic Ovary Syndrome; PRL Prolactin; T3 Triiodothyronine; T4 Thyroxine; TSH Thyroid Stimulating Hormone.
  2. a: With the exception of prolactin, data are presented as the mean ± standard error of mean (SEM).
  3. b: Prolactin was a non-normally distributed variable and data are presented as the median, first (1th) and third (3th) quartiles.
  4. c: Statistically significant p values shown as bold.
Back to article page